Beta Bionics
Builds the iLet automated insulin delivery system for type 1 diabetes.
$20.11
After-hours close+0.41 (+2.08%)
At close$19.70(+0.82%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 107.49%Insiders 2.75%
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 44.99M · Float 20.04M · 44.5% free float
Institutions13F, as of Jun 30, 2026
138 holders · 48.36M shares · 32 new positions · 90 increased · 35 reduced · 25 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Eventide Asset Management, LLC | 6.25M | 13.90% | +308.2K | Aug 14, 2026 |
| Soleus Capital Management, L.P. | 4.39M | 9.77% | +39.2K | Aug 11, 2026 |
| Morgan Stanley | 4.27M | 9.48% | +39.2K | Aug 13, 2026 |
| Sands Capital Ventures, LLC | 3.71M | 8.24% | 0 | Aug 13, 2026 |
| BlackRock, Inc. | 3.34M | 7.42% | +301.6K | Aug 7, 2026 |
| Point72 Asset Management, L.P. | 2.25M | 5.01% | −270.4K | Aug 14, 2026 |
| Vanguard Capital Management LLC | 1.78M | 3.96% | +54.4K | Aug 13, 2026 |
| Vestal Point Capital, LP | 1.60M | 3.56% | −611.5K | Aug 14, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Eventide Asset Management, LLC | 13.40% | 5.95M | 13G | May 15, 2026 ↗ |
| Morgan Stanley | 8.60% | 3.74M | 13G | Nov 7, 2025 ↗ |
| Sands Capital Life Sciences Pulse Fund II. L.P. | 8.20% | 3.57M | 13G | Aug 13, 2025 ↗ |
| Divisadero Street Capital Management, LP | 6.90% | 3.07M | 13G | Jul 24, 2026 ↗ |
| BlackRock, Inc. | 6.40% | 2.78M | 13G | Oct 17, 2025 ↗ |
| Zone Healthcare Holdings, LLC | 5.80% | 2.56M | 13G | May 12, 2026 ↗ |
| Point72 Asset Management, L.P. | 5.20% | 2.29M | 13G | Feb 23, 2026 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Sean Saint | director, officer: President & CEO | 420.9K | 0.94% | Jun 3, 2026 |
| Mike Mensinger | officer: Chief Product Officer | 184.4K | 0.41% | Jun 3, 2026 |
| Steven Jon Russell | officer: Chief Medical Officer | 173.8K | 0.39% | Jun 3, 2026 |
| Stephen Feider | officer: Chief Financial Officer | 166.1K | 0.37% | Jul 2, 2026 |
| Mark Hopman | officer: Chief Commercial Officer | 129.4K | 0.29% | Jun 25, 2026 |
| Gerard J. Michel | director | 33.5K | 0.07% | May 26, 2026 |
| Sean Carney | director | 32.2K | 0.07% | May 26, 2026 |
| Danny L. Dearen | director | 32.2K | 0.07% | May 26, 2026 |
| Maria Palasis | director | 29.4K | 0.07% | May 26, 2026 |
| Christy Jones | director | 26.0K | 0.06% | Jun 25, 2026 |
1 ten-percent owner holds 2.90M shares by Form 4, outside the officers-and-directors figure above · 1 person has not refiled in the last 18 months (38.1K shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Jun 26, 2026 | Stephen Feiderofficer: Chief Financial Officer | Sale | 5,104 | $17.05 | 166,053 |
| Jun 29, 2026 | Stephen Feiderofficer: Chief Financial Officer | Sale | 4,896 | $17.03 | 166,053 |
| Jun 24, 2026 | Christy Jonesdirector | Sale | 1,406 | $15.00 | 25,994 |
| Jun 24, 2026 | Mark Hopmanofficer: Chief Commercial Officer | Sale | 1,258 | $15.01 | 129,354 |
| Jun 4, 2026 | Christy Jonesdirector | Sale | 2,811 | $14.00 | 27,400 |
| Jun 4, 2026 | Mark Hopmanofficer: Chief Commercial Officer | Sale | 275 | $12.31 | 130,612 |
| Jun 2, 2026 | Sean Saintdirector, officer: President & CEO | Sale | 16,872 | $12.61 | 420,937 |
| Jun 2, 2026 | Stephen Feiderofficer: Chief Financial Officer | Sale | 6,676 | $12.61 | 166,053 |
| Jun 2, 2026 | Steven Jon Russellofficer: Chief Medical Officer | Sale | 4,222 | $12.61 | 173,849 |
| Jun 2, 2026 | Mark Hopmanofficer: Chief Commercial Officer | Sale | 5,329 | $12.61 | 130,887 |
CongressHouse and Senate disclosures
Not reported.